文献速递血液净化与透析

口服ghrelin受体激动剂MK-0677可提高血液透析患者的血清胰岛素样生长因子1:一项随机盲法研究

Oral ghrelin receptor agonist MK-0677 increases serum insulin-like growth factor 1 in hemodialysis patients: a randomized blinded study.
PubMed 文献 · Nephrol Dial Transplant · 2018-01-01

本研究为随机交叉双盲研究,比较口服ghrelin受体激动剂MK-0677与安慰剂对血液透析患者胰岛素样生长因子1(IGF-1)水平的影响。26例受试者入组,22例完成3个月交叉研究。MK-0677组IGF-1几何均值升高1.76倍(95%CI 1.48-2.10;P<0.001),安慰剂组为1.07倍(95%CI 0.89-1.27;P=0.718);校正干预前IGF-1后,MK-0677相对安慰剂的几何均值比为1.65(95%CI 1.33-2.04;P<0.001)。未发现归因于MK-0677的严重不良事件。

要点

  • MK-0677组IGF-1几何均值升高1.76倍(95%CI 1.48-2.10;P<0.001),安慰剂组为1.07倍(95%CI 0.89-1.27;P=0.718)。
  • 校正干预前IGF-1后,MK-0677相对安慰剂的几何均值比为1.65(95%CI 1.33-2.04;P<0.001)。
  • 未发现归因于MK-0677的严重不良事件。

核心结论

  • MK-0677可提高血液透析患者的血清IGF-1水平,且不良反应轻微。
  • 需要研究评估MK-0677长期治疗能否改善CKD/ESRD患者的蛋白质能量消耗、瘦体重、体力、生活质量和生存。

研究设计与样本

  • 随机交叉双盲研究,评估MK-0677与安慰剂对血液透析患者IGF-1水平(主要结局)的影响。
  • 共26例受试者入组,22例完成3个月交叉研究。

主要发现

  • 安慰剂后IGF-1几何均值为基线的1.07倍(95%CI 0.89-1.27;P=0.718)。
  • 接受MK-0677的患者IGF-1几何均值为基线的1.76倍(95%CI 1.48-2.10;P<0.001)。
  • 校正干预前IGF-1浓度后,MK-0677相对安慰剂的干预前后IGF-1变化几何均值比为1.65(95%CI 1.33-2.04;P<0.001)。
  • MK-0677组IGF-1升高幅度较安慰剂组高65%(95%CI 33-104%)。
  • 未发现归因于MK-0677的严重不良事件。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 需要研究评估MK-0677长期治疗能否改善CKD/ESRD患者的蛋白质能量消耗、瘦体重、体力、生活质量和生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Protein-energy wasting (PEW) in end-stage renal disease (ESRD) patients is associated with increased morbidity and mortality, but options for treatment are limited. Growth hormone (GH) increases insulin-like growth factor 1 (IGF-1), with improved nutritional parameters, but must be given subcutaneously and does not provide normal GH secretion patterns. MK-0677, an oral ghrelin receptor agonist (GRA), maintains normal GH secretion and increases lean body mass in normal subjects; it has not been studied in dialysis patients, an essential step in assessing efficacy and safety prior to clinical trials. METHODS: We performed a randomized crossover double-blind study in assessing the effect of MK-0677 versus placebo on IGF-1 levels, the primary outcome, in hemodialysis patients. In total, 26 subjects enrolled and 22 completed the 3-month crossover study. RESULTS: The geometric mean IGF-1 was 1.07-fold greater [95% confidence interval (CI) 0.89-1.27; P = 0.718] after placebo. In patients receiving MK-0677, the geometric mean IGF-1 were 1.76-fold greater (95% CI 1.48-2.10; P < 0.001) following MK-0677. When the data were adjusted for preintervention IGF-1 concentration, the ratio of geometric means (MK-0677 relative to placebo) for the pre- versus postintervention change in the IGF-1 was 1.65 (95% CI 1.33-2.04; P < 0.001). These data demonstrate a 65% greater increase (95% CI 33-104%) in IGF-1 in MK-0677-dosed subjects compared with placebo. There were no serious adverse effects attributable to MK-0677. CONCLUSIONS: MK-0677 increased serum IGF-1 levels with minimal adverse effects in hemodialysis subjects. Studies are needed to evaluate whether long-term therapy with MK-0677 improves PEW, lean body mass, physical strength, quality of life and survival in CKD/ESRD patients.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Campbell GA, Patrie JT, Gaylinn BD, et al. Oral ghrelin receptor agonist MK-0677 increases serum insulin-like growth factor 1 in hemodialysis patients: a randomized blinded study. Nephrol Dial Transplant. 2018. PMID: 28340044. doi:10.1093/ndt/gfw474

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。